Search

Copyright of Chinese Journal of Immunology is the property of Medical Periodical Society of Jilin and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To study the relationship between the angiomotin (Amot) and Yes-associated protein 1 (YAP1) expression and clinicopathological parameters and prognosis in type I endometrial cancer (EC) tissues. Methods: 75 type I EC patients who were diagnosed and treated in Affiliated Hospital of Xuzhou Medical University from January 2014 to June 2017 were selected as the study object (EC group), 30 patients with pathologically confirmed atypical hyperplasia endometrial tissue specimens diagnosed and treated during the same period were selected as the atypical hyperplasia endometrial group, and 30 patients with pathologically confirmed normal endometrial tissue specimens during the same period were selected as the normal endometrial group. The Amot and YAP1 protein expressions in each group were detected by immunohistochemistry. Spearman rank correlation was used to analyze the correlation between Amot and YAP1 protein expression in type I EC cancer tissues. The differences of Amot and YAP1 protein expression in cancer tissues of type I EC patients with different clinicopathological characteristics were compared. Kaplan-Meier analysis (Log-rank test) was used to analyze the relationship between the expression of Amot and YAP1 protein and the survival prognosis of type I EC patients. Univariate and multivariate COX regression analysis was used to analyze the factors affecting the survival prognosis of type I EC patients. Results: The positive rates of Amot and YAP1 protein expression in type I EC tissues were 80.00%(60/75) and 85.33%(64/75), respectively, which were significantly higher than those in atypical hyperplasia endometrial tissue 43.33% (13/30) and 46.67% (14/30), and the difference was statistically significant (all P＜0.05). The positive rates of Amot and YAP1 protein in atypical hyperplasia endometrial tissue were significantly higher than those in normal endometrial tissue with 16.67% (5/30) and 20.00% (6/30), and the difference was statistically significant (all P＜0.05). There was a significant positive correlation between Amot and YAP1 protein expression in type I EC cancer tissues(P＜0.05). The positive rates of Amot and YAP1 protein expression in EC type I patients with different International Federation of Gynecology and Obstetrics (FIGO) stages, histological grades and lymph node metastasis were statistically significant (P＜0.05). The cumulative survival time of Amot-positive expression typeⅠEC patients was significantly lower than that of Amot-negative expression typeⅠEC patients (P＜0.05). The cumulative survival time of patients with YAP1-positive expression of typeⅠEC was significantly lower than that of patients with YAP1-negative expression of typeⅠEC (P＜0.05). Amot-positive expression, YAP1 positive expression, FIGO stage Ⅲ and lymph node metastasis were independent risk factors for poor prognosis in patients with EC type I (P＜0.05). Conclusion: The Amot and YAP1 protein positive expression increased in type I EC cancer tissues, which are related to FIGO stage, histological grade and lymph node metastasis. The positive expression of Amot protein and YAP1 protein is one of the risk factors affecting the poor prognosis of patients with type I EC. [ABSTRACT FROM AUTHOR]

Copyright of Journal of China Medical University is the property of Journal of China Medical University Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Too many types of congenital esophageal atresia with a great diversity and variability bring dilemmas to clinical management. In clinical cases of first-stage end-to-end esophageal anastomosis, operative failure and error occur frequently due to inaccurate preoperative examinations and evaluations. Subsequent treatment becomes extremely difficult so that therapeutic efficacy is poor. Subsequent complications and sequelae adversely affect the quality of life. Based upon an etiological analysis of actual clinical cases, this review proposed practical and feasible clinical measures of avoid surgical failures and operative errors to improve the therapeutic outcomes of esophageal atresia. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Neurosurgery / Linchuang Shenjingwaike Zazhi is the property of Editorial Board of Journal of Clinical Neurosurgery and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的探讨术前血清白蛋白水平检测对结直肠癌患者根治术后预后的评估价值。方法选择行根治术 并获得长期随访的187例结直肠癌患者。术前检测患者血清白蛋白水平，将术前血清白蛋白矣37.0 g/L的患者92 例作为水平降低组，>37.0 g/L的患者95例作为水平正常组。对比分析两组临床资料。术后随访5年，统计患者 生存情况及复发情况。采用Kaplan-Meier进行生存分析，采用COX回归进行多因素分析。结果两组性别、年 龄、肿瘤部位比较，P均>0. 05;水平降低组肿瘤直径≥5 cm、低分化、浸润深度T4期、有淋巴结转移的比例高于水 平正常组(P均<0.05)。水平降低组中位生存时间低于水平正常组，复发率高于水平正常组（P均<0.05)。浸润 深度、淋巴结转移及血清白蛋白水平是根治术后结直肠癌患者预后的影响因素（P均<0.05)。结论术前血清白 蛋白水平检测可评估结直肠癌患者根治术后的预后;血清白蛋白水平越低患者预后越差。 [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Lung Cancer is the property of Chinese Journal of Lung Cancer and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)